Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label multicenter study of SHR-1701 combined with famitinib malate in advanced malignant solid tumors
CTR20202300Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2021
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa, famitinib in Nonhematologic neoplasms, sponsored by Hengrui Therapeutics. Started Apr 2021; status: active.
02
Drugs
retlirafusp alfafamitinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20202300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202300.